Clinical Trial Update: A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase II study evaluating IGEV with or without bortezomib before high-dose consolidation in relapsed/refractory Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• IGEV

Snippet

Sponsor: Istituto Clinico Humanitas | Conditions: Hodgkin Disease | Phase 2 | Status: COMPLETED